Literature DB >> 26169402

Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.

Frédéric Peyrusson1, Deborah Butler2, Paul M Tulkens1, Françoise Van Bambeke3.   

Abstract

GSK1322322 is a peptide deformylase inhibitor active against Staphylococcus aureus strains resistant to currently marketed antibiotics. Our aim was to assess the activity of GSK1322322 against intracellular S. aureus using an in vitro pharmacodynamic model and, in parallel, to examine its cellular pharmacokinetics and intracellular disposition. For intracellular activity analysis, we used an established model of human THP-1 monocytes and tested one fully susceptible S. aureus strain (ATCC 25923) and 8 clinical strains with resistance to oxacillin, vancomycin, daptomycin, macrolides, clindamycin, linezolid, or moxifloxacin. Uptake, accumulation, release, and subcellular distribution (cell fractionation) of [(14)C]GSK1322322 were examined in uninfected murine J774 macrophages and uninfected and infected THP-1 monocytes. GSK1322322 demonstrated a uniform activity against the intracellular forms of all S. aureus strains tested, disregarding their resistance phenotypes, with a maximal relative efficacy (E max) of a 0.5 to 1 log10 CFU decrease compared to the original inoculum within 24 h and a static concentration (C s) close to its MIC in broth. Influx and efflux were very fast (<5 min to equilibrium), and accumulation was about 4-fold, with no or a minimal effect of the broad-spectrum eukaryotic efflux transporter inhibitors gemfibrozil and verapamil. GSK1322322 was recovered in the cell-soluble fraction and was dissociated from the main subcellular organelles and from bacteria (in infected cells). The results of this study show that GSK1322322, as a typical novel deformylase inhibitor, may act against intracellular forms of S. aureus. They also suggest that GSK1322322 has the ability to freely diffuse into and out of eukaryotic cells as well as within subcellular compartments.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169402      PMCID: PMC4538490          DOI: 10.1128/AAC.00827-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2005-04-28       Impact factor: 5.790

2.  Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.

Authors:  Ralph Corey; Odin J Naderer; William D O'Riordan; Etienne Dumont; Lori S Jones; Milena Kurtinecz; John Z Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

3.  Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages.

Authors:  M B Carlier; B Scorneaux; A Zenebergh; J F Desnottes; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

Review 4.  Staphylococcus aureus host cell invasion and post-invasion events.

Authors:  Bhanu Sinha; Martin Fraunholz
Journal:  Int J Med Microbiol       Date:  2009-09-24       Impact factor: 3.473

5.  Intracellular persisting Staphylococcus aureus is the major pathogen in recurrent tonsillitis.

Authors:  Andreas E Zautner; Merit Krause; Gerhard Stropahl; Silva Holtfreter; Hagen Frickmann; Claudia Maletzki; Bernd Kreikemeyer; Hans Wilhelm Pau; Andreas Podbielski
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

6.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

7.  Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.

Authors:  Karen O'Dwyer; Meredith Hackel; Sarah Hightower; Daryl Hoban; Samuel Bouchillon; Donghui Qin; Kelly Aubart; Magdalena Zalacain; Deborah Butler
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

8.  Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

Authors:  M B Carlier; A Zenebergh; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

9.  Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation.

Authors:  D Mazel; S Pochet; P Marlière
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

Review 10.  Recurrent Challenges for Clinicians: Emergence of Methicillin-Resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options.

Authors:  Bansidhar Tarai; Poonam Das; Dilip Kumar
Journal:  J Lab Physicians       Date:  2013-07
View more
  6 in total

1.  Ginsenoside 20(S)-Rh2 promotes cellular pharmacokinetics and intracellular antibacterial activity of levofloxacin against Staphylococcus aureus through drug efflux inhibition and subcellular stabilization.

Authors:  Xiao-Yang Chen; Fei Qian; Yao-Yao Wang; Yan Liu; Yuan Sun; Wei-Bin Zha; Kun Hao; Fang Zhou; Guang-Ji Wang; Jing-Wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-08-30       Impact factor: 6.150

Review 2.  Antimicrobial Peptides Controlling Resistant Bacteria in Animal Production.

Authors:  Gisele Rodrigues; Lucas Souza Santos; Octávio Luiz Franco
Journal:  Front Microbiol       Date:  2022-05-19       Impact factor: 6.064

3.  Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.

Authors:  Jian-Xin Song; Zi-Jin Dian; Yan Wen; Fen Mei; Rui-Wei Li; Ya-Lian Sa
Journal:  Biomed Res Int       Date:  2016-11-24       Impact factor: 3.411

4.  Effective Antimicrobial Activity of Plectasin-Derived Antimicrobial Peptides against Staphylococcus aureus Infection in Mammary Glands.

Authors:  Lianbin Li; Liangliang Wang; Yuqi Gao; Jianhua Wang; Xin Zhao
Journal:  Front Microbiol       Date:  2017-12-04       Impact factor: 5.640

5.  Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.

Authors:  Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  The Inhibition and Resistance Mechanisms of Actinonin, Isolated from Marine Streptomyces sp. NHF165, against Vibrio anguillarum.

Authors:  Na Yang; Chaomin Sun
Journal:  Front Microbiol       Date:  2016-09-13       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.